No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Results Express Announcement
Shanghai MicuRx Pharmaceutical Leads Our Top 3 Penny Stock Selections
Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Express News | MediKang Pharmaceuticals: It is expected that the net income loss for 2024 will be between 0.44 billion yuan and 0.48 billion yuan.
Shanghai MicuRx Pharmaceutical's Phase 1 Trial for Non-Tuberculous Mycobacteria Drug Gets China Nod